We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor.
- Authors
Yin Wuq; Pfeifer, Andreas Klaus; Myschetzky, Rebecca; Garbyal, Rajendra Singh; Rasmussen, Palle; Knigge, Ulrich; Bzorek, Michael; Kristensen, Michael Holmsgaard; Kjaer, Andreas
- Abstract
Peptide receptor radionuclide therapy (PRRT) is a relatively new mode of internally targeted radiotherapy currently in clinical trials. In PRRT, ionizing radioisotopes conjugated to somatostatin analogues are targeted to neuroendocrine tumors (NETs) via somatostatin receptors. Despite promising clinical results, very little is known about the mechanism of tumor control. By using NCI-H727 cells in an in vivo murine xenograft model of human NETs, we showed that 177Lu-DOTATATE PRRT led to increased infiltration of CD86+ antigen presenting cells into tumor tissue. We also found that following treatment with PRRT, there was significantly increased tumor infiltration by CD49b+/FasL+ NK cells potentially capable of tumor killing. Further investigation into the immunomodulatory effects of PRRT will be essential in improving treatment efficacy.
- Subjects
ANTINEOPLASTIC agents; IMMUNE response; PEPTIDE receptors; RADIOISOTOPES; NEUROENDOCRINE tumors; SOMATOSTATIN; XENOGRAFTS
- Publication
Diagnostics (2075-4418), 2013, Vol 3, Issue 4, p344
- ISSN
2075-4418
- Publication type
Article
- DOI
10.3390/diagnostics3040344